CF
MBRX icon

Centaurus Financial’s Moleculin Biotech MBRX Stock Holding History

Centaurus Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed -$11K – 641
2019
Q3 		$11K Buy
+4
New +$10.3K ﹤0.01% 444
2018
Q3 		– Sell
-3
Closed -$13K – 1417
2018
Q2 		$13K Buy
+3
New +$12.3K ﹤0.01% 1448

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Centaurus Financial's MBRX Position: Q4 2019 in Review

Centaurus Financial sold out of Moleculin Biotech (MBRX) in Q4 2019, closing a stake of 4 shares — an estimated $11K sold.

Centaurus Financial first reported a position in MBRX in Q2 2018 and held it in 2 quarters. The position peaked at $13K in Q2 2018. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2019.

  • Centaurus Financial reported no remaining Moleculin Biotech position as of Q4 2019 after selling out during the quarter.
  • Centaurus Financial sold 4 Moleculin Biotech shares in Q4 2019, an estimated $11K.
  • Centaurus Financial first reported a position in Moleculin Biotech in Q2 2018 and held it in 2 quarters.
  • Centaurus Financial's Moleculin Biotech position peaked at $13K in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2019.

Based on Centaurus Financial's 13F filing for Q4 2019, filed 12 Feb 2020.